Bayer Pharma Aktiengesellschaft

Bayer Schering Pharma Ag

Astrazeneca Ab

Schering Aktiengesellschaft

Piramal Imaging Sa

Bayer Aktiengesellschaft

Dana-farber-cancer Institute Inc.

Bayer Intellectual Property Gmbh

The Broad Institute, Inc.

Mitsui Chemicals Agro, Inc.

Mitsui Chemicals Crop & Life Solutions, Inc.

Markus Berger

Werner Skuballa

Johannes Platzek

Philip Lienau

Hartmut Rehwinkel

Stefan Jaroch

Heike Schaecke

Norbert Schmees

Konrad Krolikiewicz

Jessica Lohrke

Anders Eriksson

Martin Hemmerling

Stinabritt Nilsson

Thomas Frenzel

Duy Nguyen

Christoph-Stephan Hilger

Olaf Panknin

Gregor Jost

Karl Henrik Edman

Hubertus Pietsch

Anne Mengel

Matti Juhani Lepistö

Nafizal Hossain

Ulrich Klar

Manfred Lehmann

Balint Gabos

Gerhard Siemeister

Andreas Menrad

Martin Kruger

Shinichi Banba

Holger Siebeneicher

Magnus Munck Af Rosenschöld

Darren Mckerrecher

Matti Juhani Lepisto

Yoji Aoki

Ulf Bömer

Knut Eis

Matthew Meyerson

Detlev Sülzle

Volker Schulze

Ursula Mönning

Thomas Brumby

Amaury Ernesto Fernandez-Montalvan

Sven Wittrock

Didier Roche

Kirstin Petersen

Stefan Kaulfuss

Keith Graham

Stephan Siegel

Heidi Greulich

Antonius Ter Laak

Laura Furst

Stefan Baeurle

Thomas Hansson

Detlev Suelzle

Heike Schäcke

Svetlana Ivanova

Dieter Moosmayer

Simon Anthony Herbert

Jens Schröder

Krister Henriksson

Darren McKerrecher

Michael Niehues

Tomas Klingstedt

Jan Dahmen

Per Tomas Klingstedt

Jan Dahmén

Arndt J G Schottelius

Jörg Willuda

Michael Reinhardt

Franziska Siegel

Martin Krüger

Jorma Hassfeld

Uwe Eberspächer

Roman Hillig

Thomas Zollner

Camilla Taflin

Klaus Bosslet

Ekkehard May

Jan Hübner

Daniel Korr

Steven Corsello

Lars Baerfacker

Matyas Gorjanacz

Stefan Bäurle

Vincent Rodeschini

Lena Kristina Bergstrom

Bethany Kaplan

Christian Lechner

Bkkehard May

Hassan Youssef Harb

Heike Schäecke

Phi Manh Dinh

Amael Madec

Adelaide Clara Faria Alvares De Lemos

Mrinal Shekhar

Douglas Orsi

An aqueous pharmaceutical composition including compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclododecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

Gadolinium chelate compounds for use in magnetic resonance imaging

A compound represented by Formula (1) can be used as a prolonged ectoparasite-controlling agent for an animal. A preparation for systemic application for use in prolonged control of an ectoparasite in an animal include the compound. A method for prolonged control of an ectoparasite on an animal includes systemically applying the compound. The compound may be used for preparing a medicament for prolonged control of an ectoparasite on an animal. A horticultural or agricultural insecticide containing the compound, and a method of protecting a crop from a harmful organism is also provided.

Prolonged ectoparasite-controlling agent for animal

The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging

A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

Compounds of formula (I) processes for their production and their use as pharmaceuticals. 

4H-pyrrolo[3,2-c]pyridin-4-one derivatives

The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents. 

A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[{2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl} amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

The invention relates to furane derivatives of formula (I) as inhibitors of ATAD2, a process for their preparation and use thereof. 

Furane derivatives as inhibitors of ATAD2

The present invention relates to compounds of formula I, processes for their production and their use as anti-inflammatory agents.

5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents

The present invention relates to novel fluorine containing compounds, methods for their preparation, the intermediates of the synthesis, their use as diagnostic agents, especially for imaging of thrombi. The invention relates to positron emission tomography (PET) agents and associated precursor reagents, and methods for producing such radiolaveled agents for imaging of thrombi in a mammalian body. More particularly, the invention relates to small nonpeptide, high-affinity, specific-binding glycoprotein IIb/IIIa antagonists for imaging of thrombi.

Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi

A compound of formula Ia:  The present invention relates to novel indazolyl derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments.

Phenyl and benzodioxinyl substituted indazoles derivatives

A compound of formula Ia:  The present invention relates to novel indazolyl derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments

The present invention relates to novel fluorine containing compounds, methods for their preparation, the intermediates of the synthesis, their use as diagnostic agents, especially for imaging of thrombi. The invention relates to positron emission tomography (PET) agents and associated precursor reagents, and methods for producing such radiolaveled agents for imaging of thrombi in a mammalian body. More particularly, the invention relates to small nonpeptide, high-affinity, specific-binding glycoprotein 11b/IIIa antagonists for imaging of thrombi.

Compounds for binding to the platelet specific glycoprotein IIB/IIIA and their use for imaging of thrombi

Growing community of inventors

Berlin, Germany

Markus Berger